Institutional Ownership
Lyell Immunopharma Inc
CUSIP 55083R203COM NEWLYELQ1 2026
13D / 13G Filings
5
Schedule 13D/13G on record
Beneficial Filers
5
Distinct reporting persons
Largest Stake
13.0%
Max % of class reported
Institutional Holders
69
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
5 filings · latest Nov 14, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Nov 14, 2025 | Foresite Capital Fund IV, L.P. | 13G/A | 11.0% | 1.45M | SEC |
| 2 | Nov 14, 2025 | Arch Venture Fund Ix, L.P. | 13G/A | 13.0% | 2.76M | SEC |
| 3 | Nov 13, 2025 | Innovative Cellular Therapeutics Holdings Ltd | 13G | 11.0% | 1.90M | SEC |
| 4 | Nov 12, 2025 | Newton (Ptc) Limited | 13G/A | 3.9% | 754.7K | SEC |
| 5 | Aug 1, 2025 | Gates Frontier, LLC | 13G | 11.0% | 1.04M | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Arch Venture Management, LLC | 3.25M | $65.14M |
| 2 | Gsk PLC | 1.51M | $30.34M |
| 3 | Foresite Capital Management IV, LLC | 800.4K | $16.06M |
| 4 | Orland Properties Ltd | 754.7K | $15.14M |
| 5 | Almitas Capital LLC | 577.8K | $11.59M |
| 6 | Foresite Capital Management V, LLC | 477.1K | $9.57M |
| 7 | Millennium Management LLC | 458.9K | $9.21M |
| 8 | Citadel Advisors LLC | 381.5K | $7.65M |
| 9 | Venbio Partners LLC | 337.7K | $6.77M |
| 10 | Susquehanna International Group, LLP | 310.2K | $6.22M |